The latest report by IMARC Group, titled "Digital Dose Inhaler Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028", offers a comprehensive analysis of the industry, which comprises insights on the global digital dose inhaler market share. The global digital dose inhaler market size reached US$ 2.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2028, exhibiting a growth rate (CAGR) of 14.6% during 2023-2028.
Digital dose inhalers are used by patients who have asthma and chronic obstructive pulmonary disease (COPD). They have sensors that track the time of medication administration and offer a low-dose warning indicator. Besides this, they have large display screens for easy accessibility and understanding by varied patients. As they are integrated with advanced technology to enable the automatic transfer of data, they are gaining immense traction across the globe.
Request for a sample copy of this report: https://www.imarcgroup.com/digital-dose-inhaler-market/requestsample
Digital Dose Inhaler Market Trends and Drivers:
There is currently a growing prevalence of chronic respiratory diseases (CRDs), such as lung disorders, bronchial asthma, and pulmonary hypertension (PH), which can be accredited to rising pollution levels and occupational dust exposure. This represents one of the key factors positively influencing the demand for digital dose inhalers around the world. Besides this, governing agencies of several countries and non-governmental organizations (NGOs) are spreading awareness about CRDs and available treatments. This is strengthening the growth of the market. The market is further propelled by the introduction of capsule-based and disposable dry powder inhaler (DPI) devices.
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Type:
- Branded Medication
- Generics Medication
Breakup by Product:
- Metered Dose Inhaler
- Dry Powder Inhaler
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- 3M Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Limited
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Lupin Limited
- Novartis AG
- OPKO Health Inc.
- Propeller Health (ResMed)
- Sensirion AG Switzerland
- Teva Pharmaceutical Industries Ltd.
Ask Analyst for Sample Report: https://www.imarcgroup.com/request?type=report&id=3986&flag=F
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
Email: [email protected]
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal